Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Long Term Responses to Fludarabine and Rituximab in Waldenstrom’s Macroglobulinemia

Steven Treon, MD, PhD, Andrew Branagan, Leukothea Ioakimidis, PhD, Jacob Soumerai, Christopher Patterson, MD, Parveen Wasi, MD, FRCP(C), Christos Emmanouilides, MD, PhD, Stanley R. Frankel, MD, T. Andrew Lister, MD, Pierre Morel, MD, Jeffrey Matous, MD, Stephanie A. Gregory, MD, Eva K. Kimby, MD, PhD

Blood (2008) 112 (11): 3057.

https://doi.org/10.1182/blood.V112.11.3057.3057

Published: 2008

Journal Articles

Durable Complete Responses Following Therapy with Epratuzumab Plus Rituximab: Final Efficacy Results of a Multicenter Study in Recurrent Indolent Non-Hodgkin’s Lymphoma (NHL).

John P. Leonard, MD, Stephen J. Schuster, MD, Christos Emmanouilides, MD, Felix Couture, MD, Nick Teoh, PhD, William A. Wegener, MD, PhD, David M. Goldenberg, ScD, MD

Blood (2007) 110 (11): 3419.

https://doi.org/10.1182/blood.V110.11.3419.3419

Published: 2007

Journal Articles

Long-Term Survival Is Comparable between Palifermin-Treated and Placebo-Treated Patients (Pts) with Hematologic Malignancies (HM) Undergoing High-Dose Chemotherapy and Total Body Irradiation Followed by Autologous Hematopoietic Stem Cell Transplantation (HSCT).

Ricardo Spielberger, MD, Christos Emmanouilides, MD, William Bensinger, MD, Alan Rong, PhD, Alessandra Cesano, MD, Patrick Stiff, MD

Blood (2005) 106 (11): 2925.

https://doi.org/10.1182/blood.V106.11.2925.2925

Published: 2005

Journal Articles

Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Induces Long-Term Responses in Patients with Relapsed or Refractory Follicular Lymphoma (FL).

Russell J. Schilder, MD, Thomas E. Witzig, MD, Ian Flinn, MD, Leo I. Gordon, MD, Christos Emmanouilides, MD, Hua Wang, MS, Katie Vo, Arturo Molina, MD.

Blood (2004) 104 (11): 2629.

https://doi.org/10.1182/blood.V104.11.2629.2629

Published: 2004

Journal Articles

Evaluation of Baseline Body-Weight Dosing of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

Gregory Wiseman, MD, Peter Conti, MD, Katie Vo, Russell J. Schilder, MD, Paul Foster, MD, Leo I. Gordon, MD, Christos Emmanouilides, MD, Dan Silverman, MD, Thomas E. Witzig, MD, Arturo Molina, MD

Blood (2004) 104 (11): 2634.

https://doi.org/10.1182/blood.V104.11.2634.2634

Published: 2004

NARROW

Long Term Responses to Fludarabine and Rituximab in Waldenstrom’s Macroglobulinemia

Durable Complete Responses Following Therapy with Epratuzumab Plus Rituximab: Final Efficacy Results of a Multicenter Study in Recurrent Indolent Non-Hodgkin’s Lymphoma (NHL).

Long-Term Survival Is Comparable between Palifermin-Treated and Placebo-Treated Patients (Pts) with Hematologic Malignancies (HM) Undergoing High-Dose Chemotherapy and Total Body Irradiation Followed by Autologous Hematopoietic Stem Cell Transplantation (HSCT).

Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Induces Long-Term Responses in Patients with Relapsed or Refractory Follicular Lymphoma (FL).

Evaluation of Baseline Body-Weight Dosing of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

Long Term Responses to Fludarabine and Rituximab in Waldenstrom’s Macroglobulinemia

Durable Complete Responses Following Therapy with Epratuzumab Plus Rituximab: Final Efficacy Results of a Multicenter Study in Recurrent Indolent Non-Hodgkin’s Lymphoma (NHL).

Long-Term Survival Is Comparable between Palifermin-Treated and Placebo-Treated Patients (Pts) with Hematologic Malignancies (HM) Undergoing High-Dose Chemotherapy and Total Body Irradiation Followed by Autologous Hematopoietic Stem Cell Transplantation (HSCT).

Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Induces Long-Term Responses in Patients with Relapsed or Refractory Follicular Lymphoma (FL).

Evaluation of Baseline Body-Weight Dosing of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only